AGRX vs. TPST, AADI, MIRA, ACXP, XLO, IMRX, CUE, RVPH, LPCN, and AKTX
Should you be buying Agile Therapeutics stock or one of its competitors? The main competitors of Agile Therapeutics include Tempest Therapeutics (TPST), Aadi Bioscience (AADI), MIRA Pharmaceuticals (MIRA), Acurx Pharmaceuticals (ACXP), Xilio Therapeutics (XLO), Immuneering (IMRX), Cue Biopharma (CUE), Reviva Pharmaceuticals (RVPH), Lipocine (LPCN), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical preparations" industry.
Agile Therapeutics (NASDAQ:AGRX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.
In the previous week, Agile Therapeutics and Agile Therapeutics both had 1 articles in the media. Tempest Therapeutics' average media sentiment score of 1.87 beat Agile Therapeutics' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media.
Agile Therapeutics received 329 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 66.35% of users gave Agile Therapeutics an outperform vote while only 64.63% of users gave Tempest Therapeutics an outperform vote.
Agile Therapeutics has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.
Agile Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.73, indicating that its share price is 273% less volatile than the S&P 500.
10.9% of Agile Therapeutics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 0.5% of Agile Therapeutics shares are held by insiders. Comparatively, 3.3% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Tempest Therapeutics has a net margin of 0.00% compared to Agile Therapeutics' net margin of -36.24%. Agile Therapeutics' return on equity of 0.00% beat Tempest Therapeutics' return on equity.
Agile Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 249.65%. Tempest Therapeutics has a consensus price target of $20.75, indicating a potential upside of 1,127.81%. Given Tempest Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tempest Therapeutics is more favorable than Agile Therapeutics.
Summary
Tempest Therapeutics beats Agile Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Agile Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agile Therapeutics Competitors List
Related Companies and Tools
Free AGRX Stock Alerts